

Literatura ACTA MEDICINAE 2–3/2024 Diabetologie | Kardiologie

- 3 Zlepšuje se farmakologická prevence cévních mozkových příhod u pacientů s diabetem? Z diabetologického registru**
MUDr. Martina Nováková | MUDr. Lucie Tománková Geriatrická interní klinika, 2. LF UK a FN v Motole, Praha
Mgr. Klára Benešová | RNDr. Jiří Jarkovský, Ph.D. Ústav zdravotnických informací a statistiky ČR, Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno
doc. MUDr. Iva Holmerová, Ph.D. Centrum pro studium dlouhověkosti a dlouhodobé péče FHS UK, Praha
prof. RNDr. Ladislav Dušek, Ph.D. Ústav zdravotnických informací a statistiky ČR, Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno
prof. MUDr. Milan Kvapil, CSc., MBA Geriatrická interní klinika, 2. LF UK a FN v Motole, Praha
- 3 Prediabetes – současný pohled a zamyšlení nad perspektivou jeho prevence a léčby**
doc. MUDr. Alena Šmahelová, Ph.D. III. interní gerontometabolická klinika LF UK a FN Hradec Králové
- 3 Význam časně terapie semaglutidem pro snížení kardiovaskulárního rizika**
MUDr. Marta Šimůnková
- 4 Proč není bazální inzulin obsolentní terapií**
prof. MUDr. Jan Škrha, DrSc., MBA III. interní klinika 1. lékařské fakulty Univerzity Karlovy a Všeobecné fakultní nemocnice, Praha
- 4 Novinky ve farmakoterapii diabetického onemocnění ledvin**
MUDr. Jan Vachek, MBA Klinika nefrologie 1. LF UK a VFN v Praze, Interní oddělení a HDS Klatovské nemocnice
MUDr. Kateřina Oulehle Interní oddělení a HDS Klatovské nemocnice, Klatovy
MUDr. Oskar Zakiyanov, Ph.D. Klinika nefrologie 1. LF UK a VFN v Praze
MUDr. Hana Ciferská, Ph.D. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
prof. MUDr. Vladimír Tesař, DrSc. Klinika nefrologie 1. LF UK a VFN v Praze
- 5 Praktický přístup k prevenci a léčbě chronického onemocnění ledvin u pacienta s diabetem**
prof. MUDr. Kateřina Štechová, Ph.D. Interní klinika 2. LF UK a FN v Motole, Praha
- 5 Jak může poznat selhané srdce svého pacienta diabetolog a jaké má aktuální možnosti prevence a léčby**
doc. MUDr. Denisa Janíčková Žďárská, Ph.D. Interní klinika 1. LF UK a ÚVN, Praha
- 5 Tyreopatie a diabetes**
MUDr. Markéta Paclíková III. interní gerontometabolická klinika LF UK a FN Hradec Králové
- 5 Metreleptin: nové možnosti terapie generalizované lipodystrofie**
prof. MUDr. Milan Kvapil, CSc., MBA Geriatrická interní klinika 2. LF UK a FN v Motole, Praha
- 5 Obezita a reprodukce**
MUDr. Štěpán Budka Centrum asistované reprodukce EUROPE IVF, Ambulance Gynekologie a porodnictví GYO, Gynekologicko-porodnické oddělení, Fakultní Thomayerova nemocnice, Praha

- 6 **Hypertenze v klinické praxi**
prof. MUDr. Miroslav Souček, CSc. II. interní klinika, LF MU a ICRC FN u sv. Anny v Brně
- 6 **Léčba hypertenze v těhotenství**
prof. MUDr. Renata Cífková, CSc. Centrum kardiovaskulární prevence 1. LF UK a Fakultní Thomayerovy nemocnice, Praha, II. interní klinika 1. LF UK a Všeobecné fakultní nemocnice v Praze
- 6 **Prediabetik s arteriální hypertenzí**
prof. MUDr. Hana Rosolová, DrSc. Centrum preventivní kardiologie, 2. interní klinika, LF UK a FN v Plzni
- 7 **Léčba srdečního selhání se zachovanou ejekční frakcí levé komory**
MUDr. Karel Lábr, Ph.D. | MUDr. Monika Špinarová, Ph.D., MSc. I. interní kardiologická klinika, Fakultní nemocnice u sv. Anny v Brně a LF MU, Brno
- 7 **Nové trendy v léčbě fibrilace síní**
MUDr. Ondřej Toman, Ph.D., MHA Interní kardiologická klinika, FN Brno
- 7 **Strategie hypolipidemické léčby**
doc. MUDr. Ľubica Cibičková, Ph.D. III. interní klinika – nefrologická, revmatologická a endokrinologická, FN Olomouc a LF UP v Olomouci
- 7 **Betablokátory po infarktu myokardu bez projevů srdečního selhání**
prof. MUDr. Jiří Vítovec, CSc. | MUDr. Monika Špinarová, MSc., Ph.D. I. interní kardiologická klinika MU a FN u sv. Anny v Brně
- 7 **Farmakologická léčba kardiomyopatií**
MUDr. Anna Chaloupka, Ph.D. I. interní kardiologická klinika, LF MU a FN u sv. Anny v Brně
- 8 **Studie HEART-FID vnesla nové světlo do stanovování deficitu železa u pacientů se srdečním selháním**
MUDr. Mária Bakošová I. interní kardiologická klinika, LF MU a FN u sv. Anny v Brně
- 8 **Kyselina bempedoová – nová možnost hypolipidemické léčby**
MUDr. Marta Šimůnková
- 8 **Chronické uzávěry koronárních tepen a jejich revaskularizace**
MUDr. Veronika Bednářová | doc. MUDr. Vladimír Kincl, Ph.D. | MUDr. Jiří Seménka | prof. MUDr. Jan Krejčí, Ph.D. I. interní kardiologická klinika FN u sv. Anny v Brně, ICRC, LF MU, Brno
- 8 **Výhody nebivololu v ovlivnění endoteliální dysfunkce a v prevenci rozvoje hypertenzí mediovaného orgánového poškození – betablokátory v léčbě hypertenze**
MUDr. Petra Vysočanová I. interní kardiologická klinika, FN Brno a LF MU, Brno
- 9 **Inclisiran v léčbě dyslipidemie u pacientů se stenózou tepen**
MUDr. Jan Lacko Lipidová poradna, Nemocnice Třebíč, regionální centrum projektu MedPed

Zlepšuje se farmakologická prevence cévních mozkových příhod u pacientů s diabetem? Z diabetologického registru

MUDr. Martina Nováková | MUDr. Lucie Tománková Geriatrická interní klinika, 2. LF UK a FN v Motole, Praha

Mgr. Klára Benešová | RNDr. Jiří Jarkovský, Ph.D. Ústav zdravotnických informací a statistiky ČR, Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno

doc. MUDr. Iva Holmerová, Ph.D. Centrum pro studium dlouhodobosti a dlouhodobé péče FHS UK, Praha

prof. RNDr. Ladislav Dušek, Ph.D. Ústav zdravotnických informací a statistiky ČR, Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno

prof. MUDr. Milan Kvapil, CSc., MBA Geriatrická interní klinika, 2. LF UK a FN v Motole, Praha

- 1 Václavík D.: Primární a sekundární prevence ischemických cévních mozkových příhod. *Kardiol Rev Int Med*, 2013, 15, s. 37–40.
- 2 Wilcox, R. – Bousser, M. G. – Betteridge, D. J., et al.; PROactive Investigators: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitazone Clinical Trial In macroVascular Events 04). *Stroke*, 2007, 38, s. 865–873.
- 3 Kernan, W. N. – Viscoli, C. M. – Furie, K. L., et al.; IRIS trial investigators: Pioglitazone after ischemic stroke or transient ischemic attack. *N Engl J Med*, 2016, 374, s. 1321–1331.
- 4 Qin, J. – Song, L.: Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials. *BMC Endocr Disord*, 2022, 22, s. 125.
- 5 Yang, Y. S. – Chen, H. H. – Huang, C. N., et al.: GLP-1RAs for ischemic stroke prevention in patients with type 2 diabetes without established atherosclerotic cardiovascular disease. *Diabetes Care*, 2022, 45, s. 1184–1192.
- 6 Strain, W. D. – Frenkel, O. – James, M. A., et al.: Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6. *Stroke*, 2022, 53, s. 2749–2757.
- 7 Kvapil, M., et al.: *Diabetologie*. Triton, Praha, 2023.

Prediabetes – současný pohled a zamyšlení nad perspektivou jeho prevence a léčby

doc. MUDr. Alena Šmahelová, Ph.D. III. interní gerontometabolická klinika LF UK a FN Hradec Králové

- 1 Davidson, K. W. – Barry, M. J. – Mangione, C. M., et al.: Screening for prediabetes and type 2 diabetes: US preventive services task force recommendation statement. *JAMA*, 2021, 326, s. 736–743.
- 2 Neves, J. S. – Newman, C. – Bostrom, J. A., et al.: Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes. *Diabetes Res Clin Pract*, 2022, 190, 109980.
- 3 Shu, Y. – Wu, X. – Wang, J., et al.: Associations of dietary inflammatory index with prediabetes and insulin resistance. *Front Endocrinol*, 2022, 13, 820932.
- 4 Zhu, X. – Yang, Z. – He, Z., et al.: Factors correlated with targeted prevention for prediabetes classified by impaired fasting glucose, impaired glucose tolerance, and elevated HbA_{1c}: A population-based longitudinal study. *Front Endocrinol*, 2022, 13, 965890.
- 5 American Diabetes Association Professional Practice Committee: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. *Diabetes Care*, 2024, 47, suppl. 1, s. S158–S178.
- 6 Gujral, U. P. – Jagannathan, R. – He, S., et al.: Association between varying cut-points of intermediate hyperglycemia and risk of mortality, cardiovascular events and chronic kidney disease: a systematic review and meta-analysis. *BMJ Open Diabetes Res Care*, 2021, 9, e001776.
- 7 Wang, X. – Huang, C. – Liu, Y., et al.: Association of estimated glomerular filtration rate and incident pre-diabetes: A secondary 5-year longitudinal cohort study in Chinese people. *Front Endocrinol*, 2022, doi.org/10.3389/fendo.2022.965545.
- 8 Sanz, M. – Ceriello, A. – Buyschaert, M., et al.: Scientific evidence on the links between periodontal diseases and diabetes: consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the international diabetes federation and the European federation of periodontology. *J Clin Periodontol*, 2018, 45, s. 138–149.
- 9 Liao, W.-Ch. – Tu, Y. K. – Wu, M. S., et al.: Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis. *BMJ*, 2015, 350, g7371.
- 10 Diabetes Prevention Program Research Group: Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. *Lancet Diabetes Endocrinol*, 2015, 3, s. 866–875.
- 11 Aroda, V. R. – Edelstein, S. L. – Goldberg, R. B., et al.; Diabetes Prevention Program Research Group: Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. *J Clin Endocrinol Metab*, 2016, 101, s. 1754–1761.
- 12 Defronzo, R. A. – Tripathy, D. – Schwenke, D. C., et al.; ACT NOW Study: Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. *Diabetes*, 2013, 62, s. 3920–3926.
- 13 Cloro, C. – Zaffina, I. – Sacchetta, L., et al.: Effects of sacubitril/valsartan on both metabolic parameters and insulin resistance in prediabetic non-obese patients with heart failure and reduced ejection fraction. *Front Endocrinol*, 2022, 13, 940654.
- 14 Wang, W. – Wei, R. – Huang, Z., et al.: Effects of treatment with glucagon-like peptide-1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta-analysis. *Diabetes Metab Res Rev*, 2023, 39, e3680.
- 15 le Roux, C. W. – Astrup, A. – Fujioka, K., et al.; SCALE Obesity Prediabetes NN8022-1839 Study Group: 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet*, 2017, 389, s. 1399–1409.
- 16 Karen, I. – Svačina, Š.: *Prediabetes. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře 2022*. Centrum doporučených postupů pro praktické lékaře. Společnost všeobecného lékařství, Praha, s. 1–12.
- 17 Neves, J. S. – Buyschaert, M. – Bergman, M.: Editorial: Prediabetes: new insights on the diagnosis, risk stratification, comorbidities, cardiovascular disease, microvascular complications, and treatment. *Front Endocrinol*, 2023, 14, 1214479.

Význam časně terapie semaglutidem pro snížení kardiovaskulárního rizika

MUDr. Marta Šimůnková

- 1 Karásek, D.: Orální semaglutid – Rybelsus, první agonista GLP-1 receptoru pro perorální využití v klinické praxi. *Vnitř Lék*, 2022, 68, s. 89–95.
- 2 Žourek, M.: Léčba diabetiků zralého věku agonisty GLP-1 – cesta k dlouhodobosti? Souhrn přednášky z cyklu seminářů Diabetologie 2022. *Medical Tribune CZ* 27. 6. 2023.
- 3 Kirstensen, S. L., et al.: Cardiovascular mortality and kidney outcomes with GLP-1 receptor agonists in patient with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet Diabetes Endocrinol*, 2019, 10, s. 776–785.
- 4 Haluzík, M.: Inkretinová léčba diabetu a kardiovaskulární komplikace. *Vnitř Lék*, 2020, 66, s. 74–80.
- 5 Holman, R. R. – Paul, S. K. – Bethel, M. A., et al.: 10-year follow up of intensive glucose control in type 2 diabetes. *N Engl J Med*, 2008, 359, s. 1577–1589.
- 6 Nissen, S. E. – Wolski, K.: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med*, 2007, 356, s. 2457–2471.
- 7 Sodhi, M., et al.: Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. *JAMA*, 2023, 18, s. 1795–1797.
- 8 Ozempic. Souhrn údajů o přípravku. EMA, poslední revize 3/2023.
- 9 Holst, J. J. – Gromada, J.: Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. *Am J Physiol Endocrinol Metab*, 2004, 287, s. E199–E206.
- 10 Sharma, A. – Verma, S.: Mechanisms by which glucagon like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors reduce cardiovascular risk in adults with type 2 diabetes mellitus. *Can J Diabetes*, 2020, 44, s. 93–102.
- 11 Buse, J. B. – Wexler, D. J. – Tsapas, A., et al.: 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, 2020, 43, s. 487–493.
- 12 Dahl, K. – Brooks, A. – Almazedi, F., et al.: Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. *Diabetes Obes Metab*, 2021, 23, s. 1594–1603.
- 13 Sattar, N. – Lee, M. M. Y. – Kristensen, S. L., et al.: Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *Lancet Diabetes Endocrinol*, 2021, 9, s. 653–662.
- 14 Lincoff, A. M. – Brown-Frandsen, K. – Colhoun, H. M., et al.; on behalf of the SELECT Trial Investigators: Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med*, 2023, 389, s. 2221–2232.
- 15 Davies, M. – Pieber, T. R. – Hartoft Nielsen, M. L., et al.: Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. *JAMA*, 2017, 318, s. 1460–1470.

Proč není bazální inzulin obsolentní terapií

prof. MUDr. Jan Škrha, DrSc., MBA III. interní klinika 1. lékařské fakulty Univerzity Karlovy a Všeobecné fakultní nemocnice, Praha

- Gubitosi-Klug, R. A., et al.: Risk of severe hypoglycemia in type 1 diabetes over 30 years of follow-up in the DCCT/EDIC study. *Diabetes Care*, 2017, 40, s. 1010–1016.
- Gerstein, H. C., et al.: Basal insulin and cardiovascular and other outcomes in dysglycemia. The ORIGIN Trial investigators. *New Engl J Med*, 2012, 367, s. 319–328.
- Little, S., et al.: Hypoglycemia rates with basal insulin analogs. *Diab Technol Therap*, 2011, 13, suppl. 1, s. S53–S64.
- Heller, S., et al.: Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet*, 2012, 379, s. 1489–1497.
- Garber, A. J., et al.: Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet*, 2012, 379, s. 1498–1507.
- Blonde, L., et al.: Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme. *Diab Obes Metab*, 2021, 23, s. 1713–1721.
- Soupal, J., et al.: Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR Study. *Diabetes Care*, 2020, 43, s. 37–43.
- Wang, H. Y., et al.: Basal insulin reduces glucose variability and hypoglycaemia compared to premixed insulin in type 2 diabetes patients: a study based on continuous glucose monitoring systems. *Front Endocrinol*, 2022, 13, 791439.
- Singh, A. K., et al.: Once-weekly basal insulin icodex: Looking ONWARDS from pharmacology to clinical trials. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 2022, 16, 102615.
- Heise, T., et al.: Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. *Diabetes Obes Metab*, 2023, 25, s. 1080–1090.

Novinky ve farmakoterapii diabetického onemocnění ledvin

MUDr. Jan Vachek, MBA Klinika nefrologie 1. LF UK a VFN v Praze, Interní oddělení a HDS Klatovské nemocnice

MUDr. Kateřina Oulehle Interní oddělení a HDS Klatovské nemocnice, Klatovy

MUDr. Oskar Zakijonov, Ph.D. Klinika nefrologie 1. LF UK a VFN v Praze

MUDr. Hana Ciferská, Ph.D. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

prof. MUDr. Vladimír Tesař, DrSc. Klinika nefrologie 1. LF UK a VFN v Praze

- Garg, A. X. – Kiberd, B. A. – Clark, W. F., et al.: Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. *Kidney Int*, 2002, 61, s. 2165–2175.
- Kidney Disease: Improving Global Outcomes Diabetes Working Group: KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. *Kidney Int*, 2022, 102, s. S1–S127.
- Jin, Q. – Luk, A. O. – Lau, E. S. H., et al.: Hong Kong Diabetes Biobank Study Group: Nonalbuminuric diabetic kidney disease and risk of all-cause mortality and cardiovascular and kidney outcomes in type 2 diabetes: findings from the Hong Kong Diabetes Biobank. *Am J Kidney Dis*, 2022, 80, s. 196–206.e1.
- Jankowski, J. – Floege, J. – Fliser, D., et al.: Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. *Circulation*, 2021, 143, s. 115.
- Go, A. S. – Chertow, G. M. – Fan, D., et al.: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*, 2004, 351, s. 1296–1305.
- Abbott, K. – Basta, E. – Bakris, G. L.: Blood pressure control and nephroprotection in diabetes. *J Clin Pharmacol*, 2004, 44, s. 431–438.
- Sarnak, M. J. – Levey, A. S. – Schoolwerth, A. C., et al.: American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation*, 2003, 108, s. 2154–2169.
- Lewis, E. J. – Hunsicker, L. G. – Bain, R. P., et al.: Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. *N Engl J Med*, 1993, 329, s. 1456–1462.
- Brenner, B. M. – Cooper, M. E. – de Zeeuw, D., et al.: RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*, 2001, 345, s. 861–869.
- Ma, Y. – Lin, C. – Cai, X., et al.: Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysis. *Acta Diabetol*, 2023, 60, s. 435–445.
- Kintscher, U. – Bakris, G. L. – Kolkhof, P.: Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. *Br J Pharmacol*, 2022, 179, s. 3220–3234.
- Tuttle, K. R. – Agarwal, R. – Alpers, C. E., et al.: Molecular mechanisms and therapeutic targets for diabetic kidney disease. *Kidney Int*, 2022, 102, s. 248–260.
- Ruiz-Ortega, M. – Lorenzo, O. – Suzuki, Y., et al.: Proinflammatory actions of angiotensins. *Curr Opin Nephrol Hypertens*, 2001, 10, s. 321–329.
- Hostetter, T. H.: Hyperfiltration and glomerulosclerosis. *Semin Nephrol*, 2003, 23, s. 194–199.
- Eaton, D. C. – Pooler, J. P. (eds.): *Vander's Renal Physiology*. McGraw Hill, 2023. Dostupné z: <https://accessmedicine.mhmedical.com/content.aspx?bookid=3316§ionid=2716338176>, vyhledáno 4. 3. 2024.
- Smith, A. C. – Toto, R. – Bakris, G. L.: Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. *Kidney Int*, 1998, 54, s. 889–896.
- Tuttle, K. R.: Back to the future: glomerular hyperfiltration and the diabetic kidney. *Diabetes*, 2017, 66, s. 14–16.
- Heerspink, H. J. – Perkins, B. A. – Fitchett, D. H., et al.: Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. *Circulation*, 2016, 134, s. 752–772.
- Grabias, B. M. – Konstantopoulos, K.: The physical basis of renal fibrosis: effects of altered hydrodynamic forces on kidney homeostasis. *Am J Physiol Renal Physiol*, 2014, 306, s. F473–F485.
- Tsimihodimos, V. – Filippatos, T. D. – Filippas-Ntekouan, S., et al.: Renoprotective effects of SGLT2 inhibitors: beyond glucose reabsorption inhibition. *Curr Vasc Pharmacol*, 2017, 15, s. 96–102.
- Ferrannini, E.: Sodium-glucose co-transporters and their inhibition: clinical physiology. *Cell Metab*, 2017, 26, s. 27–38.
- Hojs, R. – Ekart, R. – Bevc, S., et al.: Markers of inflammation and oxidative stress in the development and progression of renal disease in diabetic patients. *Nephron*, 2016, 133, s. 159–162.
- Dou, L. – Jourde-Chiche, N.: Endothelial toxicity of high glucose and its by-products in diabetic kidney disease. *Toxins*, 2019, 11, s. 57.
- Barrera-Chimal, J. – Girerd, S. – Jaissner, F.: Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. *Kidney Int*, 2019, 96, s. 302–319.
- Cantero-Navarro, E. – Rayego-Mateos, S. – Orejudo, M., et al.: Role of macrophages and related cytokines in kidney disease. *Front Med*, 2021, 8, 688060.
- Bakris, G. L. – Agarwal, R. – Chan, J. C., et al.: Mineralocorticoid Receptor Antagonist–Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group: Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. *JAMA*, 2015, 314, s. 884–894.
- Holtkamp, F. A. – de Zeeuw, D. – de Graeff, P. A., et al.: Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. *Eur Heart J*, 2011, 32, s. 1493–1499.
- McGuire, D. K. – Shih, W. J. – Cosentino, F., et al.: Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. *JAMA Cardiol*, 2021, 6, s. 148–158.
- Perkovic, V. – Jardine, M. J. – Neal, B., et al.: CRENDENCE Trial Investigators: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*, 2019, 380, s. 2295–2306.
- Heerspink, H. J. L. – Stefánsson, B. V. – Correa-Rotter, R., et al.: DAPA-CKD Trial Committees and Investigators: Dapagliflozin in patients with chronic kidney disease. *N Engl J Med*, 2020, 383, s. 1436–1446.
- EMPA-KIDNEY Collaborative Group: Empagliflozin in patients with chronic kidney disease. *N Engl J Med*, 2023, 388, s. 117–127.
- Quach, K. – Ltvyn, L. – Baigent, C., et al.: The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta-analysis. *Am J Kidney Dis*, 2016, 68, s. 591–598.
- Bakris, G. L. – Agarwal, R. – Anker, S. D., et al.: FIDELIO-DKD Investigators: Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med*, 2020, 383, s. 2219–2229.
- Filippatos, G. – Anker, S. D. – Agarwal, R., et al.: FIGARO-DKD Investigators: Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. *Circulation*, 2022, 145, s. 437–447.
- Agarwal, R. – Filippatos, G. – Pitt, B., et al.: FIDELIO-DKD and FIGARO-DKD Investigators: Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. *Eur Heart J*, 2022, 43, s. 474–484.
- Marso, S. P. – Bain, S. C. – Conzoli, A., et al.: SUSTAIN-6 Investigators: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*, 2016, 375, s. 1834–1844.
- Shaman, A. M. – Bain, S. C. – Bakris, G. L., et al.: Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. *Circulation*, 2022, 145, s. 575–585.
- Lam, C. S. P. – Ramasundarahettige, C. – Branch, K. R. H., et al.: Efficacy and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. *Circulation*, 2022, 145, s. 565–574.
- Mann, J. F. E. – Buse, J. B. – Idorn, T., et al.: Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis. *Diabetes Obes Metab*, 2021, 23, s. 2058–2066.
- Ejlerblad, E. – Fored, C. M. – Lindblad, P., et al.: Obesity and risk for chronic renal failure. *J Am Soc Nephrol*, 2006, 17, s. 1695–1702.
- Novo Nordisk A/S. A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW). ClinicalTrials.gov. Bethesda, MD, National Library of Medicine, 2019.
- de Boer, I. H. – Khunti, K. – Sadusky, T., et al.: Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Diabetes Care*, 2022, 45, s. 3075–3090.
- Kolkhof, P. – Hartmann, E. – Freyberger, A., et al.: Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. *Am J Nephrol*, 2021, 52, s. 642–652.
- Provenzano, M. – Puchades, M. J. – Garofalo, C., et al.: ROTATE-3 Study Group: ROTATE-3 Study Group Members: Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. *J Am Soc Nephrol*, 2022, 33, s. 1569–1580.
- Agarwal, R. – Joseph, A. – Anker, S. D., et al.: FIDELIO-DKD Investigators: Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. *J Am Soc Nephrol*, 2022, 33, s. 225–237.
- Neuen, B. L. – Oshima, M. – Perkovic, V., et al.: Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CRENDENCE trial. *Eur Heart J*, 2021, 42, s. 4891–4901.
- Green, J. B. – Mottl, A. K. – Bakris, G., et al.: Design of the combination effect of finerenone and empagliflozin in participants with chronic kidney disease and type 2 diabetes using an UACR endpoint study (CONFIDENCE). *Nephrol Dial Transplant*, 2022, 38, s. 894–903.
- Naaman, S. C. – Bakris, G. L.: Diabetic nephropathy: update on pillars of therapy slowing progression. *Diabetes Care*, 2023, 46, s. 1574–1586.
- News Details (novonordisk.com).

Praktický přístup k prevenci a léčbě chronického onemocnění ledvin u pacienta s diabetem

prof. MUDr. Kateřina Štechová, Ph.D. Interní klinika 2. LF UK a FN v Motole, Praha

- 1 Cases, A.: Glucagon-like peptide 1 (GLP-1) receptor agonists in the management of the patient with type 2 diabetes mellitus and chronic kidney disease: an approach for the nephrologist. *Nefrologia*, 2023, 43, s. 399–412.
- 2 Davies, M. J. – Aroda, V. R. – Collins, B. S., et al.: Management of hyperglycemia in type 2 diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, 2022, 45, s. 2753–2786.
- 3 Gourdy, P. – Darnon, P. – Dievert, F., et al.: Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). *Cardiovasc Diabetol*, 2023, 22, s. 79.
- 4 Kim, D. L. – Lee, S. E. – Kim, N. H.: Renal protection of mineralocorticoid receptor antagonist, finerenone, in diabetic kidney disease. *Endocrinol Metab*, 2023, 38, s. 43–55.
- 5 Sindhu, D. – Sharma, G. S. – Kumbala, D.: Management of diabetic kidney disease: where do we stand?: A narrative review. *Medicine*, 2023, 102, s. e33366.
- 6 Vučić Lovrenčić, M. – Božičević, S. – Smirčić Duvnjak, L.: Diagnostic challenges of diabetic kidney disease. *Biochem Med*, 2023, 33, 030501, doi: 10.11613/BM.2023.030501.
- 7 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW). Dostupné z: <https://clinicaltrials.gov/study/NCT03819153#study-overview>, vyhledáno 12. 1. 2024.
- 8 A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) (REMODEL). Dostupné z: <https://clinicaltrials.gov/study/NCT04865770>, vyhledáno 12. 1. 2024.
- 9 Česká diabetologická společnost. Standardy a doporučení. Dostupné z: https://www.diab.cz/dokumenty/doporučení_postupy_o_DKD.pdf; https://www.diab.cz/dokumenty/doporučení_pro_mezioborovou_spolupraci.pdf; <https://www.cisweb.cz/files/expertni-stanovisko-ke-spolupraci-diabetologu-a-internistu-s-nefrologii-final.pdf>, vyhledáno 12. 1. 2024.
- 10 Organizace KDIGO (Kidney Disease: Improving Global Outcomes). Dostupné z: <https://kdigo.org/guidelines/ckd-evaluation-and-management/>; https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2023-CKD-Guideline-Public-Review-Draft_5-July-2023.pdf, vyhledáno 12. 1. 2024.

Jak může poznat selhané srdce svého pacienta diabetolog a jaké má aktuální možnosti prevence a léčby

doc. MUDr. Denisa Janíčková Žďárská, Ph.D. Interní klinika 1. LF UK a ÚVN, Praha

- 1 Nakamura, K. – Miyoshi, T. – Yoshida, M., et al.: Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus. *Int J Mol Sci*, 2022, 23, s. 3587.
- 2 Gavina, C. – Carvalho, D. S. – Valente, F., et al.: 20 years of real-world data to estimate the prevalence of heart failure and its subtypes in an unselected population of integrated care units. *J Cardiovasc Dev Dis*, 2022, 9, s. 149.
- 3 Ritchie, R. H. – Abel, E. D.: Basic mechanisms of diabetic heart disease. *Circ Res*, 2020, 126, s. 1501–1525.
- 4 Jia, G. – Hill, M. A. – Sowers, J. R.: Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. *Circ Res*, 2018, 122, s. 624–638.
- 5 McDonagh, T. A. – Metra, M. – Adamo, M., et al.: 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2023, 44, s. 3627–3639.
- 6 Krishnaswamy, P. – Lubien, E. – Clopton, P., et al.: Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. *Am J Med*, 2001, 111, s. 274–279.
- 7 Krauser, D. G. – Lloyd-Jones, D. M. – Chae, C. U., et al.: Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. *Am Heart J*, 2005, 149, s. 744–750.
- 8 Špinar, J. – Málková, F. – Špinarová, L., et al.: Úprava guidelines ACC pro léčbu srdečního selhání v roce 2021. *Cor Vasa*, 2021, 63, s. 264–270.
- 9 Packer, M. – Anker, S. D. – Butler, J., et al.: Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med*, 2020, 383, s. 1413–1424.
- 10 McMurray, J. V. – Solomon, S. D. – Inzucchi, S. E., et al.: Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*, 2019, 381, s. 1995–2008.
- 11 Anker, S. D. – Butler, J. – Filippatos, G., et al.: Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med*, 2021, 385, s. 1451–1461.
- 12 Solomon, S. D. – McMurray, J. J. V. – Claggett, B., et al.: Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med*, 2022, 387, s. 1089–1098.
- 13 Liang, M. – Bian, B. – Yang, Q.: Characteristics and long-term prognosis of patients with reduced, mid-range, and preserved ejection fraction: A systemic review and meta-analysis. *Clin Cardiol*, 2022, 45, s. 5–17.
- 14 [www.sukl.cz: Detail léčivého přípravku Forxiga, 23. 8. 2023.](http://www.sukl.cz: Detail léčivého přípravku Forxiga, 23. 8. 2023)
- 15 [www.sukl.cz: Detail léčivého přípravku Jardiance, 31. 12. 2023.](http://www.sukl.cz: Detail léčivého přípravku Jardiance, 31. 12. 2023)

Tyreopatie a diabetes

MUDr. Markéta Paclíková III. interní gerontometabolická klinika LF UK a FN Hradec Králové

- 1 Běhanová, M. – Zamrazil, V. – Vondra, K., et al.: Klinická charakteristika tyreopatií u diabetiků středního věku. *DMEV*, 1999, 2, suppl. 1, s. 21–22.
- 2 Hansen, J., et al.: A prospective study of thyroid function morphology and autoimmunity in young patients with type 1 diabetes. *Eur J Endocrinol*, 2003, 148, s. 245–251.
- 3 Doporučený postup péče o diabetes 1. typu České diabetologické společnosti ČLS JEP, 2022.
- 4 Diabetes a tyreopatie – klinický význam. *Medical Tribune*, 12/2012. Dostupné z: <https://www.tribune.cz/archiv/diabetes-a-tyreopatie-klinicky-vyznam/>, vyhledáno 20. 2. 2024.
- 5 Zamrazil, V. – Vondra, K.: Štitná žláza a diabetes. *Interní Med*, 2007, 9.
- 6 Pelikánová, T., et al.: *Praktická diabetologie*. Maxdorf, Praha, 2018, s. 693–707.
- 7 Marek, J. – Hána, V., et al.: *Endokrinologie*. Galén, Praha, 2017.
- 8 Jiskra, J.: Choroby štítné žlázy v graviditě. *Med Praxi*, 2012, 9, s. 233–237.
- 9 Věstník MZ ČR, 11/23, www.mzcr.cz.
- 10 Jiskra, J. – Límanová, Z.: Doporučení pro prevenci, časný záchyt a léčbu tyreopatií v těhotenství 2018. *Novelizace 3/2023. ČES ČLS JEP*, s. 1–4. Dostupné z: https://endokrinologie.blob.core.windows.net/cms/ContentItems/58_00058/em1tZb/doporučení-pro-prevenci-endokrinologove-update-3-2023.pdf, vyhledáno 20. 2. 2024.

Metreleptin: nové možnosti terapie generalizované lipodystrofie

prof. MUDr. Milan Kvapil, CSc., MBA Geriatrická interní klinika 2. LF UK a FN v Motole, Praha

- 1 Perakakis, N. – Farr, O. M. – Mantzoros, C. S.: Leptin in leanness and obesity: JACC state-of-the-art review. *J Am Coll Cardiol*, 2021, 77, s. 745–760.
- 2 Araújo-Vilar, D. – Santini, F.: Diagnosis and treatment of lipodystrophy: a step-by-step approach. *J Endocrinol Invest*, 2019, 42, s. 61–73.
- 3 Brown, R. J. – Oral, E. A. – Cochran, E., et al.: Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. *Endocrine*, 2018, 60, s. 479–489.
- 4 SPC Metreleptin. Dostupné z: https://ec.europa.eu/health/documents/community-register/2020/20200428147190/aux_147190_cs.pdf, vyhledáno 25. 3. 2024.

Obezita a reprodukce

MUDr. Štěpán Budka Centrum asistované reprodukce EUROPE IVF, Ambulance Gynekologie a porodnictví GYO, Gynekologicko-porodnické oddělení, Fakultní Thomayerova nemocnice, Praha

- 1 Practice Committee of the American Society for Reproductive Medicine. Obesity and reproduction: a committee opinion. *Fertil Steril*, 2015, 104, s. 1116–1126.
- 2 Aune, D. – Saugstad, O. D. – Henriksen, T., et al.: Maternal body mass index and the risk of fetal death, stillbirth, and infant death: a systematic review and meta-analysis. *JAMA*, 2014, 311, s. 1536–1546.
- 3 Bandel, I. – Bungum, M. – Richtoff, J., et al.: No association between body mass index and sperm DNA integrity. *Hum Reprod*, 2015, 30, s. 1704–1713.
- 4 Campbell, J. M. – Lane, M. – Owens, J. A., et al.: Paternal obesity negatively affects male fertility and assisted reproduction outcomes: a systematic review and meta-analysis. *Reprod Biomed Online*, 2015, 31, s. 593–604.
- 5 Flegal, K. M. – Kit, B. K. – Orpana, H., et al.: Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *JAMA*, 2013, 309, s. 71–82.
- 6 Provost, M. P. – Acharya, K. S. – Acharya, C. R., et al.: Pregnancy outcomes decline with increasing body mass index: analysis of 239,127 fresh autologous in vitro fertilization cycles from the 2008–2010 Society for Assisted Reproductive Technology registry. *Fertil Steril*, 2016, 105, s. 663–669.
- 7 Weir, C. B. – Jan, A.: BMI Classification Percentile And Cut Off Points. 2023 Jun 26. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 31082114.
- 8 Luke, B. – Brown, M. B. – Stern, J. E., et al.: Female obesity adversely affects assisted reproductive technology pregnancy and live birth

- rates. *Human Reprod*, 2011, 26, s. 245–252.
- 9 Practice Committee of the American Society for Reproductive Medicine: Obesity and reproduction: a committee opinion. *Fertil Steril*, 2021, 116, s. 1266–1285.
- 10 Yildiz, B. O. – Knochenhauer, E. S. – Azziz, R.: Impact of obesity on the risk for polycystic ovary syndrome. *J Clin Endocrinol Metab*, 2008, 93, s. 162–168.
- 11 Pasquali, R. – Pelusi, C. – Genghini, S., et al.: Obesity and reproductive disorders in women. *Hum Reprod Update*, 2003, 9, s. 359–372.
- 12 Cnattingius, S. – Bergström, R. – Lipworth, L., et al.: Prepregnancy weight and the risk of adverse pregnancy outcomes. *N Engl J Med*, 1998, 338, s. 147–152.
- 13 Zachariah, M. – Fleming, R. – Acharya, U.: Management of obese women in assisted conception units: a UK survey. *Hum Fertil*, 2006, 9, s. 101–105.

Hypertenze v klinické praxi

prof. MUDr. Miroslav Souček, CSc. II. interní klinika, LF MU a ICRC FN u sv. Anny v Brně

- 1 Williams, B. – Mancia, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. *J Hypertens*, 2018, 36, s. 1953–2041.
- 2 Widimský, J. – Filipovský, J. – Ceral, J., et al.: Hypertenze a kardiovaskulární prevence. Diagnostické a léčebné postupy u arteriální hypertenze. Doporučení České společnosti pro hypertenzi. 2022, 1–25. Dostupné z: https://www.hypertension.cz/wp-content/uploads/2023/01/Widimsky_-guidelines-CSH-2022.pdf, vyhledáno 23. 1. 2024.
- 3 Taniwail, T. – Lustigová, M. – Brož, J., et al.: Arterial hypertension in the Czech Republic: Prevalence, awareness, and control among adult aged 25–64 in 2019: cross-sectional study. *Eur Heart J*, 2023, 44, suppl. 2.
- 4 Mancia, G. – Kreutz, J. – Brunstrom, M., et al.: 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *J Hypertens*, 2023, 41, s. 1874–2071.
- 5 Souček, M. – Kára, T., et al.: *Klinická patofyziologie hypertenze*. Praha, Grada Publishing, 2002.
- 6 Vidal-Petiot, E. – Ford, I. – Greenlaw, N., et al.: Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. *Lancet*, 2016, 388, s. 2142–2152.
- 7 Williams, B. – Mancia, G. – Spiering, W., et al.: ESC Scientific Document Group: 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*, 2018, 39/33, s. 3021–3104.
- 8 Carrao, G. – Nicotra, F. – Parodi, A., et al.: Cardiovascular prevention by initial and subsequent combination of antihypertensive drugs in daily life practice. *Hypertension*, 2011, 58, s. 566–572.
- 9 Mazzaglia, G. – Ambrosioni, E. – Alacqua, M., et al.: Adherence to antihypertensive medication and cardiovascular morbidity a mortality among newly diagnosed hypertensive patients. *Circulation*, 2009, 12, s. 1598–1605.
- 10 Štrauch, B. – Petrák, O. – Zelinka, T., et al.: Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. *J Hypertens*, 2013, 31, s. 1455–2461.
- 11 Gupta, A. K. – Patel, P. – Strauch, B., et al.: Risk factors for nonadherence to antihypertensive treatment. *Hypertension*, 2017, 69, s. 1113–1120.
- 12 Van Wijck, B. L. G. – Klungel, O. H. – Heerding, E. R.: Rate and determination of 10-year persistence with antihypertensive drug. *J Hypertens*, 2005, 23, s. 2101–2107.
- 13 Rosolová, H.: Adherence a perzistence k léčbě. *Svět praktické medicíny*, 2021, 3, s. 38–40.
- 14 Reas, F. – Corrao, G. – Luca Merlino, L., et al.: Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. *Eur Heart J*, 2018, 39, s. 3654–3661.
- 15 Gupta, A. K. – Arshad, S. – Poulter, N. R.: Compliance, safety and effectiveness of fixed dose combinations of antihypertensive agents: a meta-analysis. *Hypertension*, 2010, 55, s. 399–407.
- 16 Suvila, K. – McCabe, E. L. – Lehtonen, A., et al.: Early onset hypertension associated with hypertensive end-organ damage already by midlife. *Hypertension*, 2019, 74, s. 305–312.

Léčba hypertenze v těhotenství

prof. MUDr. Renata Cífková, CSc. Centrum kardiovaskulární prevence 1. LF UK a Fakultní Thomayerovy nemocnice, Praha, II. interní klinika 1. LF UK a Všeobecné fakultní nemocnice v Praze

- 1 Regitz-Zagrosek, V. – Roos-Hesslink, J. W. – Bauersachs, J. – Blomström-Lundqvist, C. – Cífková, R., et al.: ESC Scientific Document Group: 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J*, 2018, 39, s. 3165–3241.
- 2 Mancia, G. – Kreutz, R. – Brunström, M., et al.: 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *J Hypertens*, 2023, 41, s. 1874–2071.
- 3 Brown, M. A. – Magee, L. A. – Kenny, L. C., et al.: Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. *Hypertension*, 2018, 72, s. 24–43.
- 4 Roberge, S. – Nicolaidis, K. – Demers, S., et al.: The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. *Am J Obstet Gynecol*, 2017, 216, s. 110–120.e6.
- 5 Roberge, S. – Giguère, Y. – Villa, P., et al.: Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. *Am J Perinatol*, 2012, 29, s. 551–556.
- 6 Thomopoulos, C. – Salamalekis, G. – Kintis, K., et al.: Risk of hypertensive disorders in pregnancy following assisted reproductive technology: overview and meta-analysis. *J Clin Hypertens*, 2017, 19, s. 173–83.
- 7 Williams, B. – Mancia, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. *J Hypertens*, 2018, 36, s. 1953–2041.
- 8 Tita, A. T. – Szychowski, J. M. – Boggess, K., et al.: Treatment for mild chronic hypertension during pregnancy. *N Engl J Med*, 2022, 386, s. 1781–1792.
- 9 Magee, L. A. – von Dadelszen, P. – Rey, E., et al.: Less-tight versus tight control of hypertension in pregnancy. *N Engl J Med*, 2015, 372, s. 407–417.
- 10 Leddy, M. A. – Power, M. L. – Schulkin, J.: The impact of maternal obesity on maternal and fetal health. *Rev Obstet Gynecol*, 2008, 1, s. 170–178.
- 11 Mottola, M. F. – Davenport, M. H. – Ruchat, S. M., et al.: 2019 Canadian guideline for physical activity throughout pregnancy. *Br J Sports Med*, 2018, 52, s. 1339–1346.
- 12 Garovic, V. D. – Dechend, R. – Easterling, T., et al.: Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. *Hypertension*, 2022, 79, s. e21–e41.
- 13 Kayser, A. – Beck, E. – Hoeltzenbein, M., et al.: Neonatal effects of intrauterine metoprolol/bisoprolol exposure during the second and third trimester: a cohort study with two comparison groups. *J Hypertens*, 2020, 38, s. 354–361.
- 14 Grossman, E. – Messerli, F. H. – Grodzicki, T., et al.: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseud emergencies? *JAMA*, 1996, 276, s. 1328–1331.
- 15 Magee, L. A. – Cham, C. – Waterman, E. J., et al.: Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. *BMJ*, 2003, 327, s. 955–960.
- 16 Coppage, K. H. – Sibai, B. M.: Treatment of hypertensive complications in pregnancy. *Curr Pharm Des*, 2005, 11, s. 749–757.
- 17 Cífková, R. – Johnson, M. R. – Kahan, T., et al.: Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. *Eur Heart J Cardiovasc Pharmacother*, 2020, 6, s. 384–393.
- 18 Podymow, T. – August, P.: Antihypertensive drugs in pregnancy. *Semin Nephrol*, 2011, 31, s. 70–85.
- 19 Jónsdóttir, L. S. – Amgrímsson, R. – Geirsson, R. T., et al.: Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. *Acta Obstet Gynecol Scand*, 1995, 74, s. 772–776.
- 20 Paradisi, G. – Biaggi, A. – Savone, R., et al.: Cardiovascular risk factors in healthy women with previous gestational hypertension. *J Clin Endocrinol Metab*, 2006, 91, s. 1233–1238.

Prediabetik s arteriální hypertenzí

prof. MUDr. Hana Rosolová, DrSc. Centrum preventivní kardiologie, 2. interní klinika, LF UK a FN v Plzni

- 1 Alberti, K. G. – Eckel, R. H. – Grundy, S. M., et al.: Harmonizing the metabolic syndrome: A joint interim statement of the IDF Task Force on Epidemiology and Prevention, NHLBI, AHA, WHO, IAS, IASO. *Circulation*, 2009, 120, s. 1640–1645.
- 2 Leonetti, G. – Rappelli, A. – Salvetti, A., et al.: Long-term effects of indapamide: final results of a two-year Italian multicenter study in systemic hypertension. *Am J Cardiol*, 1990, 65, s. 67–71.
- 3 ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. *Lancet*, 2007, 370, s. 829–840.
- 4 De Galan, B. E. – Perkovic, V. – Ninomiya, T., et al.: Lowering blood pressure reduces renal events in type 2 diabetes. *J Am Soc Nephrol*, 2009, 20, s. 883–892.
- 5 Zoungas, S., et al.: Follow up of blood pressure lowering and glucose control in type 2 diabetes. *N Engl J Med*, 2014, 371, s. 1392–1406.
- 6 Chalmers, J. – Mourad, J. J. – Brzozowska-Villatte, R., et al.: Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials. *J Hypertens*, 2023, 41, s. 508–515.
- 7 Tremblay, J. – Haloui, M. – Attaoua, R., et al.: Polygenic risk scores predict diabetic complications and their response to intensive blood pressure and glucose control. *Diabetologia*, 2021, 64, s. 2012–2025.

Léčba srdečního selhání se zachovanou ejekční frakcí levé komory

MUDr. Karel Lábr, Ph.D. | MUDr. Monika Špinarová, Ph.D., MSc. I. interní kardiologická klinika, Fakultní nemocnice u sv. Anny v Brně a LF MU, Brno

- Reddy, Y. N. V. – Carter, R. E. – Obokata, M., et al.: A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. *Circulation*, 2018, 138, s. 861–870.
- Pieske, B. – Tschöpe, C. – de Boer, R. A., et al.: How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur Heart J*, 2019, 40, s. 3297–3317.
- Dunlay, S. M. – Roger, V. L. – Redfield, M. M.: Epidemiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol*, 2017, 14, s. 591–602.
- Seferović, P. M. – Vardas, P. – Jankowska, E. A., et al.: The Heart Failure Association Atlas: heart failure epidemiology and management statistics 2019. *Eur J Heart Fail*, 2021, 23, s. 906–914.
- McDonagh, T. A. – Metra, M. – Adamo, M., et al.: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2021, 42, s. 3599–3726.
- McDonagh, T. A. – Metra, M. – Adamo, M., et al.: 2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*, 2023, 44, s. 3627–3639.
- Anker, S. D. – Butler, J. – Filippatos, G., et al.: Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med*, 2021, 385, s. 1451–1461.
- Solomon, S. D. – McMurray, J. J. V. – Claggett, B., et al.: Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med*, 2022, 387, s. 1089–1098.
- Solomon, S. D. – McMurray, J. J. V. – Anand, I. S., et al.: Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. *N Engl J Med*, 2019, 381, s. 1609–1620.
- Heidenreich, P. A. – Bozkurt, B. – Aguilar, D., et al.: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, 2022, 145, s. E895–E1032.
- Anker, S. D. – Usman, M. S. – Anker, M. S., et al.: Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. *Eur J Heart Fail*, 2023, 25, s. 936–955.

Nové trendy v léčbě fibrilace síní

MUDr. Ondřej Toman, Ph.D., MHA Interní kardiologická klinika, FN Brno

- Benjamin, E. J. – Muntner, P. – Alonso, A., et al.: Heart disease and stroke statistics – 2019 update: a report from the American Heart Association. *Circulation*, 2019, 139, s. e56–e528.
- John, R. M. – Michaud, G. F. – Stevenson, W. G., et al.: Atrial fibrillation hospitalisation, mortality and therapy. *Eur Heart J*, 2018, 39, s. 3958–3960.
- Hindricks, G. – Potpara, T. – Dagres, N., et al.: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*, 2020, 42, s. 373–498.
- Bulková, V.: Long-term ECG monitoring. *Vnitřní Léč*, 2021, 67, s. 16–21.
- Bulková, V. – Pindor, J. – Plešinger, F., et al.: Telemedicine in arrhythmology. *Vnitřní Léč*, 2022, 68, s. 160–165.
- Osmancik, P. – Herman, P. – Neuzil, P., et al.: 4-Year outcomes after left atrial appendage closure versus non-warfarin oral anticoagulation for atrial fibrillation. *J Am Coll Cardiol*, 2022, 79, s. 1–14.
- Passman, R. – Leong-Sit, P. – Andrei, A. C., et al.: Targeted anticoagulation for atrial fibrillation guided by continuous rhythm assessment with an insertable cardiac monitor: the Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT.COM) pilot study. *J Cardiovasc Electrophysiol*, 2016, 27, s. 264–270.
- Waks, J. W. – Passman, R. S. – Matos, J., et al.: Intermittent anticoagulation guided by continuous atrial fibrillation burden monitoring using dual-chamber pacemakers and implantable cardioverter-defibrillators: Results from the Tailored Anticoagulation for Non-Continuous Atrial Fibrillation (TACTIC-AF) pilot study. *Heart Rhythm*, 2018, 15, s. 1601–1607.
- Peigh, G. – Passman, R. S.: „Pill in the pocket“ for stroke prevention in atrial fibrillation. *J Cardiovasc Electrophysiol*, 2023, 34, s. 2152–2157.
- Phlips, T. – Taghji, P. – El Haddad, M., et al.: Improving procedural and one-year outcome after contact force-guided pulmonary vein isolation: the role of interlesion distance, ablation index, and contact force variability in the „CLOSE“-protocol. *Europace*, 2018, 20, s. f419–f427.
- Reddy, V. Y. – Neuzil, P. – Koruth, J. S., et al.: Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. *J Am Coll Cardiol*, 2019, 74, s. 315–326.
- Reddy, V. Y. – Anic, A. – Koruth, J. S., et al.: Pulsed field ablation in patients with persistent atrial fibrillation. *J Am Coll Cardiol*, 2020, 76, s. 1068–1080.
- Schmidt, B. – Bordignon, S. – Neven, K., et al.: European real-world outcomes with Pulsed field ablation in patients with symptomatic atrial fibrillation: lessons from the multi-centre EU-PORIA registry. *Europace*, 2023, 25, eua1185.
- Reddy, V. Y. – Gerstenfeld, E. P. – Natale, A., et al.: Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. *N Engl J Med*, 2023, 389, s. 1660–1671.

Strategie hypolipidemické léčby

doc. MUDr. Ľubica Cibičková, Ph.D. III. interní klinika – nefrologická, revmatologická a endokrinologická, FN Olomouc a LF UP v Olomouci

- Vrablík, M. – Pitha, J. – Bláha, V., et al.: Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. *Vnitřní Léč*, 2019, 65, s. 743–754.

Další literatura u autorky

Betablokátory po infarktu myokardu bez projevů srdečního selhání

prof. MUDr. Jiří Vítovec, CSc. | MUDr. Monika Špinarová, MSc., Ph.D. I. interní kardiologická klinika MU a FN u sv. Anny v Brně

- Bangalore, S. – Makani, H. – Radford, M., et al.: Clinical outcomes with β -blockers for myocardial infarction: a meta-analysis of randomized trials. *Am J Med*, 2014, 127, s. 939–953.
- Kala, P. – Mates, M. – Želízko, M., et al.: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Cor Vasa*, 2017, 59, s. e613–e644.
- Hradec, J.: Kontroverze kolem betablokátorů. *Vnitřní Léč*, 2015, 61, s. 410–416.
- Janský, P.: Léčba betablokátory u infarktu myokardu v éře primární PČI. *Interv Akut Kardiol*, 2019, 18, s. 96–98.
- Vítovec, J. – Špinar, J. – Špinarová, L.: Betablokátory u kardiaskulárních onemocnění – pro a proti. *Kardiol Rev Int Med*, 2019, 21, s. 86–89.
- The Task Force for the management of acute coronary syndromes in patients presenting with out persistent ST-segment elevation of ESC. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*, 2020, 42, s. 1289–1367.
- Kim, J. – Kang, D. – Park, H., et al.: Long-term β -blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. *Eur Heart J*, 2020, 41, s. 3521–3529.
- Sipahi, I. – Tuzcu, E. M. – Wolski, K. E., et al.: Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. *Ann Intern Med*, 2007, 147, s. 10–18.
- Holt, A. – Blanche, P. – Zareini, B., et al.: Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients in the reperfusion era – a Danish, nationwide cohort study. *Eur Heart J*, 2021, 42, s. 907–914.
- van Diepen, S. – Armstrong, P. W.: Learning whether to subtract beta-blockers: it's about time. *Europ Heart J*, 2021, 42, s. 915–918.
- Harari, R. – Bangalore, S.: Beta-blockers after acute myocardial infarction: an old drug in urgent need of new evidence! *Europ Heart J*, 2020, 41, s. 3530–3532.
- Argulian, E. – Bangalore, S. – Messerli, F. H.: Misconceptions and facts about beta-blockers. *Amer J Med*, 2019, 132, s. 816–819.

Farmakologická léčba kardiomyopatií

MUDr. Anna Chaloupka, Ph.D. I. interní kardiologická klinika, LF MU a FN u sv. Anny v Brně

- Arbello, E. – Protonotarios, A. – Gimeno, J. R., et al.: 2023 ESC Guidelines for the management of cardiomyopathies. *Eur Heart J*, 2023, 44, s. 3503–3626.
- McDonagh, T. A. – Metra, M. – Adamo, M., et al.: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2021, 42, s. 3599–3726.
- McDonagh, T. A. – Metra, M. – Adamo, M., et al.: 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2023, 44, s. 3627–3639.
- Zeppenfeld, K. – Tfelt-Hansen, J. – de Riva, M., et al.: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *Eur Heart J*, 2022, 43, s. 3997–4126.
- Authors/Task Force members, Elliott, P. M. – Anastasakis, A., et al.: 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J*, 2014, 35, s. 2733–2779.
- Olivetto, I. – Oreziak, A. – Barriales-Villa, R., et al.: Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2020, 396, s. 759–769.
- Desai, M. Y. – Owens, A. – Geske, J. B., et al.: Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. *J Am Coll Cardiol*, 2022, 80, s. 95–108.
- Anker, S. D. – Butler, J. – Filippatos, G., et al.: Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med*, 2021, 385,

Studie HEART-FID vnesla nové světlo do stanovování deficitu železa u pacientů se srdečním selháním

MUDr. Mária Bakošová I. interní kardiologická klinika, LF MU a FN u sv. Anny v Brně

- Martens, P.: The effect of iron deficiency on cardiac function and structure in heart failure with reduced ejection fraction. Dostupné z: <https://www.cfrjournal.com/articles/effect-iron-deficiency-cardiac-function-and-structure-heart-failure-reduced-ejection>, vyhledáno 5. 3. 2023.
- Alnuwaysir, R. I. S. – Hoes, M. F. – van Veldhuisen, D. J., et al.: Iron deficiency in heart failure: mechanisms and pathophysiology. *J Clin Med*, 2021, 11, s. 125.
- Rocha, B. M. L. – Cunha, G. J. L. – Menezes Falcão, L. F.: The burden of iron deficiency in heart failure: therapeutic approach. *J Am Coll Cardiol*, 2018, 71, s. 782–793.
- Lindberg, F. – Lund, L. H. – Benson, L., et al.: Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREATinine Measurements collaborative project. *Eur J Heart Fail*, 2023, 25, s. 1270–1280.
- Anker, S. D. – Colet, J. C. – Filippatos, G., et al.: Rationale and design of Ferinject assessment in patients with Iron deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. *Eur J Heart Fail*, 2009, 11, s. 1084–1091.
- Ponikowski, P. – van Veldhuisen, D. J. – Comin-Colet, J., et al.: Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. *Eur Heart J*, 2015, 36, s. 657–668.
- Lewis, G. D. – Malhotra, R. – Hernandez, A. F., et al.: Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: The IRONOUT HF randomized clinical trial. *JAMA*, 2017, 317, s. 1958–1966.
- van Veldhuisen, D. J. – Ponikowski, P. – van der Meer, P., et al.: Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. *Circulation*, 2017, 136, s. 1374–1383.
- Ponikowski, P. – Kirwan, B. A. – Anker, S. D., et al.: Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. *Lancet*, 2020, 396, s. 1895–1904.
- Kalra, P. R. – Cleland, J. G. F. – Petrie, M. C., et al.: Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. *Lancet*, 2022, 400, s. 2199–2209.
- Mentz, R. J. – Garg, J. – Rockhold, F. W., et al.: Ferric carboxymaltose in heart failure with iron deficiency. *N Engl J Med*, 2023, 389, s. 975–986.
- McDonagh, T. A. – Metra, M. – Adamo, M., et al.: 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*, 2023, 44, s. 3627–3639.

Kyselina bempedoová – nová možnost hypolipidemické léčby

MUDr. Marta Šimůnková

- Dostupné z: eatlas.escardio.org, vyhledáno 14. 2. 2024.
- Eurostat 2022.
- Dušek, L.: Národní kardiologický informační systém, ÚZIS. Prezentováno na XXXI. výročním sjezdu České kardiologické společnosti, Brno, 13.–16. 5. 2023.
- Tůmová, E. – Vrablík, M.: Kyselina bempedoová v kontextu současných možností hypolipidemické léčby a výsledků studie CLEAR OUTCOMES. *Athero Rev*, 2023, 8, s. 85–94.
- Nilemdo. Souhrn údajů o přípravku. EMA. Datum první registrace: 1. 4. 2020.
- Souhrn k 3. hodnotící zprávě. SÚKL; 14. 9. 2023.
- Gunn, L. H. – McKay, A. J. – Feng, A., et al.: Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. *Atheroscler Plus*, 2022, 49, s. 20–27.
- Cicero, A. F. G. – Fogacci, F. – Hernandez, A. V., et al.: Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis. *PLoS Med*, 2020, 17, e1003121.
- Masson, W. – Lobo, M. – Lavallo-Cobo, A., et al.: Effect of bempedoic acid on new onset or worsening diabetes: A meta-analysis. *Diabetes Res Clin Pract*, 2020, 168, 108369.
- Nissen, S. E., et al.: Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med*, 2023, 388, s. 1353–1364.

Chronické uzávěry koronárních tepen a jejich revaskularizace

MUDr. Veronika Bednářová | doc. MUDr. Vladimír Kincl, Ph.D. | MUDr. Jiří Seménka | prof. MUDr. Jan Krejčí, Ph.D.

I. interní kardiologická klinika FN u sv. Anny v Brně, ICRC, LF MU, Brno

- Azzalini, L. – Jolicoeur, E. – Pighi, M., et al.: Epidemiology, management strategies, and outcomes of patients with chronic total coronary occlusion. *Am J Cardiol*, 2016, 118, s. 1128–1135.
- Azzalini, L. – Karpaliotis, D. – Santiago, R., et al.: Contemporary issues in chronic total occlusion percutaneous coronary intervention. *J Am Coll Cardiol Interv*, 2022, 15, s. 1–21.
- Assali, M. – Buda, K. G. – Megaly, M., et al.: Update on chronic total occlusion percutaneous coronary intervention. *Prog Cardiovasc Dis*, 2021, 69, s. 27–34.
- Marechal, P. – Davin, L. – Gach, O., et al.: Coronary chronic total occlusion intervention: utility or futility. *Expert Rev Cardiovasc Ther*, 2018, 16, s. 361–367.
- Werner, G. S. – Martin-Yuste, V. – Hildick-Smith, D., et al.: EUROCTO trial investigators: A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. *Eur Heart J*, 2018, 39, s. 2484–2493.
- Sapontis, J. – Salisbury, A. C. – Yeh, R. W., et al.: Early procedural and health status outcomes after chronic total occlusion angioplasty: a report from the OPEN-CTO registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures). *JACC Cardiovasc Interv*, 2017, 10, s. 1523–1534.
- Hachamovitch, R. – Rozanski, A., et al.: Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. *Eur Heart J*, 2011, 32, s. 1012–1024.
- Davies, R. F. – Goldberg, A. D. – Forman, S., et al.: Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: Outcomes of patients randomized to initial strategies of medical therapy versus revascularization. *Circulation*, 1997, 95, s. 2037–2043.
- Gada, H. – Kirtane, A. J. – Kereiakes, D. J., et al.: Meta-analysis of trials on mortality after percutaneous coronary intervention compared with medical therapy in patients with stable coronary heart disease and objective evidence of myocardial ischemia. *Am J Cardiol*, 2015, 115, s. 1194–1199.
- Stergiopoulos, K. – Boden, W. E. – Hartigan, P., et al.: Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: A collaborative meta-analysis of contemporary randomized clinical trials. *JAMA Intern Med*, 2014, 174, s. 232–240.
- Nishigaki, K. – Yamazaki, T. – Kitabatake, A., et al.: Japanese Stable Angina Pectoris Study Investigators: Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease: a randomized, comparative, multicenter study. *JACC Cardiovasc Interv*, 2008, 1, s. 469–479.
- Neumann, F. J. – Sousa-Uva, M. – Ahlsson, A., et al.: 2018 ESC/EACTS Guidelines on myocardial revascularization. *Europ Heart J*, 2019, 40, s. 87–165.
- Emrich, T. – Halfmann, M. – Schoepf, U. J., et al.: CMR for myocardial characterization in ischemic heart disease: state-of-the-art and future developments. *Eur Radiol Exp*, 2021, 5, s. 14.
- Murin, J.: CLARIFY registry – five-years follow-up of patients with chronic coronary syndrome. *Cardiology Lett*, 2020, 29, s. 93–96.

Výhody nebivololu v ovlivnění endoteliální dysfunkce a v prevenci rozvoje hypertenzí mediovaného orgánového poškození – betablokátory v léčbě hypertenze

MUDr. Petra Vysočanová I. interní kardiologická klinika, FN Brno a LF MU, Brno

- Mancia, G. – Kreutz, R. – Brunström, et al.: 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *J Hypertens*, 2023, 41, s. 1874–2071.
- Coats, A. – Jain, S.: Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage. *J Hum Hypertens*, 2017, 31, s. 376–381.
- Gupta, S. – Wright, H. M.: Nebivolol: a highly selective beta-1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. *Cardiovasc Ther*, 2008, 26, s. 189–202.
- Sovová, E. – Štěgnerová, L. – Sovová, M.: Betablokátory, které nemějně negativně ovlivňují kardiorespirační zdatnost u zdravých osob. *Kardiol Rev Int Med*, 2016, 18, s. 199–202.
- Slíva, J.: Nebivolol a jeho duální mechanismus účinku. *Farmakoterapie*, 2014, 10, s. 1–128.
- Ferri, C.: The role of nebivolol in the management of hypertensive patients: from pharmacological profile to treatment guidelines. *Future Cardiol*, 2021, 17, s. 1421–1433.
- Gungor, G. – Perk, H. – Soyupek, S., et al.: Nebivolol protects erectile

functions compared to metoprolol in hypertensive men with atherogenic, venogenic, psychogenic erectile dysfunction: A prospective, randomized, cross-over, clinical trial. *Eur J Intern Med*, 2022, 103,

s. 69–75.

8 **Manrique, C. – Giles, T. D. – Ferdinand, K. C., et al.**: Realities of newer beta-blockers for the management of hypertension. *J Clin Hypertens*,

2009, 11, s. 369–375.

Inclisiran v léčbě dyslipidemie u pacientů se stenózou tepen

MUDr. Jan Lacko Lipidová poradna, Nemocnice Třebíč, regionální centrum projektu MedPed

- 1 **Mach, F. – Baigent, C. – Catapano, A. L., et al.**: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). *Eur Heart J*, 2020, 41, s. 111–188.
- 2 **Visseren, F. L. J. – Mach, F. – Smulders, Y. M., et al.**: 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). *Eur Heart J*, 2021, 42, s. 3227–3337.
- 3 **Brott, T. G. – Harperin, J. L. – Abbara, S., et al.**: 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. *Stroke*, 2011, 42, s. e464–e540.
- 4 **Silesen, H. – Sartori, S., et al.**: Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. *Eur Heart J Cardiovasc Imaging*, 2018, 19, s. 1042–1050.
- 5 **Baber, U. – Mehran, R. – Sartori, S., et al.**: Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the bioimage study. *J Am Coll Cardiol*, 2015, 65, s. 1065–1074.
- 6 **Silesen, H. – Muntendan, P., et al.**: Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial disease in the high risk plaque bioimage study. *J Am Coll Cardiol Img*, 2012, 5, s. 681–689.
- 7 **Ference, B. A. – Ginsberg, H. N., et al.**: Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J*, 2017, 38, s. 2459–2472.
- 8 **Goldstein, J. L. – Brown, M. S.**: A century of cholesterol and coronaries: from plaques to genes to statins. *Cell*, 2015, 161, s. 161–172.
- 9 **Kronenberg, F. – Mora, S. – Stroes, E. S. G., et al.**: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis. European Atherosclerosis Society consensus statement. *Eur Heart J*, 2022, 43, s. 3925–3946.
- 10 **Piřha, J. – Klimořova, S. – Peregrin, J. – Źiřka, J.**: Asymptomatic stenoza karoticke tepny. *Vnitř Lek*, 2009, 55, s. 867–868.
- 11 **Ray, K. K. – Phil, M. – Wright, R. S., et al.**: ORION-10 and ORION-11 Investigators: Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. *N Engl J Med*, 2020, 382, s. 1507–1519.
- 12 **Karasek, D.**: Inclisiran – novy reprezentant biologicke lecby dyslipidemie. *Klin Farmakol Farm*, 2023, 37, s. 112–114.
- 13 SPC prpravku Leqvio, SUKL. Dostupne z: https://prehledy.sukl.cz/prehled_liciv.html#/liciva/0255591, vyhledano 18. 3. 2024.
- 14 **Bar, M. – Škoda, O. – Školoudik, D.**: Duplexnı sonografie extrakranialnıch tepen – narodnı standard vyřetenı v ramci funkcnı specializace v neurosonologii. *es a Slov Neurol N*, 2002, suppl. 2, s. 5–8.
- 15 **Bar, M. – Škoda, O. – Školoudik, D.**: Duplexnı sonografie extrakranialnıch tepen – narodnı standard vyřetenı v ramci funkcnı specializace v neurosonologii – odborna prloha. *es a Slov Neurol N*, 2002, suppl.2, s. 8–12.
- 16 **Kalita, Z. – Keller, O. – Bar, M., et al.**: Doporueny postup sekundrnı prevence recidivy po akutnı cevnı mozkove prlohade: mozkovem infarktu/transitornı ischemicke atace a hemoragicke cevnı mozkove prlohade. *esk Slov Neurol N*, 2008, 71/104, s. 372–378.
- 17 **Sinning, D. – Landmesser, U.**: Low-density lipoprotein-cholesterol lowering strategies for prevention of atherosclerotic cardiovascular disease: focus on siRNA treatment targeting PCSK9 (inclisiran). *Curr Cardiol Rep*, 2020, 22, s. 176.